ChemicalBook
Chinese Japanese Germany Korea

Sparfloxacin

Sparfloxacin
Sparfloxacin structure
CAS No.
110871-86-8
Chemical Name:
Sparfloxacin
Synonyms
Parox;ci978;Spara;Zagam;at4140;Sparcin;RP-64206;CP 103826;PD 1315-1;Sparfloxacin
CBNumber:
CB7407291
Molecular Formula:
C19H22F2N4O3
Formula Weight:
392.4
MOL File:
110871-86-8.mol

Sparfloxacin Properties

Melting point:
265°C
Boiling point:
640℃
Density 
1.436±0.06 g/cm3(Predicted)
Flash point:
>110°(230°F)
storage temp. 
Keep in dark place,Inert atmosphere,2-8°C
pka
pKa1 6.25, pKa2 9.30(at 25℃)
form 
powder
color 
white to light yellow
Water Solubility 
Soluble in DMSO at 9mg/ml. Sparingly soluble in water
BRN 
9170271
CAS DataBase Reference
110871-86-8(CAS DataBase Reference)
SAFETY
  • Risk and Safety Statements
Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H315-H319-H335
Precautionary statements  P280a-P304+P340-P405-P501a-P261-P305+P351+P338
Hazard Codes  Xi
Risk Statements  36/37/38
Safety Statements  26-36
WGK Germany  2
RTECS  VB1986500
HS Code  29339900

Sparfloxacin price More Price(8)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich 56968 Sparfloxacin ≥98.0% (HPLC) 110871-86-8 1g-f $50.9 2020-08-18 Buy
Sigma-Aldrich 56968 Sparfloxacin ≥98.0% (HPLC) 110871-86-8 10g-f $141 2020-08-18 Buy
Alfa Aesar J66358 Sparfloxacin 98% 110871-86-8 10g $129 2021-03-22 Buy
Alfa Aesar J66358 Sparfloxacin 98% 110871-86-8 1g $26.4 2021-03-22 Buy
Cayman Chemical 20379 Sparfloxacin ≥95% 110871-86-8 1g $25 2021-03-22 Buy

Sparfloxacin Chemical Properties,Uses,Production

Description

Sparfloxacin is the most potent fluoroquinolone antibiotic introduced for the treatment of community acquired infections. It has superior and broad in vitro activity against members of family Enterobacferiaceae and anaerobic bacteria, some of which are resistant toβ-lactam antibiotics or to aminoglycosides. In patients with surgical infections, sparfloxacin shows excellent activity against resistant pathogens. It is effective in treating patients with bladder irritability and is reported to have potential in the treatment of leprosy and Mycobacterium tuberculosis in mice. Favorable pharmacokinetic properties, good intracellular penetration and a lack of transferable resistance have been reported.

Chemical Properties

Light yellow powder

Originator

Dainippon (Japan)

Uses

antifungal

Uses

A fluorianted quinolone antibacterial

Manufacturing Process

A mixture of the known compound, ethyl pentafluorobenzoylacetate [J. Org. Chem., 35, 930 (1970)] (25 g), ethyl orthoformate (20 g), and acetic anhydride (23 g) was refluxed for 2 h. The reaction mixture was evaporated to dryness under reduced pressure. The residue was dissolved in diethyl ether and allowed to react with cyclopropylamine (5.1 g) to give ethyl 2- pentafluorobenzoyl-3-cyclopropylaminoacrylate (28 g), melting point 89°C.
The ethyl 2-pentafluorobenzoyl-3-cyclopropylaminoacrylate (28 g) was dissolved in dry tetrahydrofuran and allowed to react with 60% sodium hydride (3.85 g) at room temperature to give ethyl 1-cyclopropyl-5,6,7,8- tetrafluoro-1,4-dihydro-4-oxoquinoline-3-carboxylate (18.4 g), melting point 170°-171°C.
A mixture of ethyl 1-cyclopropyl-5,6,7,8-tetrafluoro-1,4-dihydro-4- oxoquinoline-3-carboxylate (28.2 g), benzylamine (9.8 ml), anhydrous potassium carbonate (23.6 g), and acetonitrile (140 ml) was heated at 100°- 110°C for 1 h to give ethyl 5-benzylamino-1-cyclopropyl-6,7,8-trifluoro-1,4- dihydro-4-oxoquinoline-3-carboxylate (21.4 g), which was recrystallized from ethanol, melting point 134°-135°C.
The ethyl 5-benzylamino-1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4- oxoquinoline-3-carboxylate (20 g) was dissolved in acetic acid (100 ml) and ethanol (150 ml), and hydrogenolyzed in the presence of 5% palladiumcarbon (0.5 g) to give ethyl 5-amino-1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro- 4-oxoquinoline-3-carboxylate (14.1 g), which was recrystallized from chloroform-ethanol, melting point 236°-237°C.
A mixture of the ethyl 5-amino-1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4- oxoquinoline-3-carboxylate (12.6 g), acetic acid (80 ml), water (50 ml), and concentrated sulfuric acid (9 ml) was heated at 100°-110°C for 40 min to give 5-amino-1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid (11.1 g), which was recrystallized from chloroform-ethanol, melting point 294°-295°C.
A mixture of 5-amino-1-cyclopropyl-6,7,8-trifluoro-1,4-dihydro-4- oxoquinoline-3-carboxylic acid (1.25 g), cis-2,6-dimethylpiperazine (2.0 g), and dimethylformamide was stirred at room tempersture for 24 h. The reaction mixture was evaporated to dryness under reduced pressure and water was added to the residue. The mixture was extracted with chloroform and the extract was dried. After evaporation of chloroform, ethanol was added to the residue. The resulting crystals were filtered and recrystallized from chloroform-ethanol to give 5-amino-1-cyclopropyl-6,8-difluoro-7-(cis-3,5- dimethyl-1-piperazinyl)-1,4-dihydro- 4-oxoquinoline-3-carboxylic acid (1.4 g), melting point: 258°-260°C.

brand name

Zagam (Mylan);Spara.

Therapeutic Function

Antibacterial

World Health Organization (WHO)

Sparfloxacin is a quinolone antimicrobial agent. See also under quinolone and fluoroquinolone antimicrobial agents.

Pharmaceutical Applications

It is highly active against most aerobic Grampositive cocci and Gram-negative bacilli, including fastidious Gram-negative bacilli, Acinetobacter spp., Campylobacter spp. and Legionella spp. Ps. aeruginosa is weakly susceptible. Activity also extends to the genital mycoplasmas, M. tuberculosis and M. avium complex isolates. It is moderately active against some anaerobes (including the B. fragilis group); L. monocytogenes is resistant.
It is well absorbed, achieving a plasma concentration of 1–1.5 mg/L 4.5 h after a 400 mg oral dose. Absorption is decreased in the presence of antacids owing to the formation of chelates with metallic ions. Concentrations in many tissues, including lung, exceed those in plasma. The plasma half-life is 15–20 h. CSF penetration is limited. Around 5–10% of a dose is eliminated unchanged in the urine, with about 30% appearing as the glucuronide. Total clearance is 10–15 L/h. The plasma half-life increases only modestly in renal failure to 30–40 h. About 50–60% of the dose appears as unchanged drug in the feces, mainly as the glucuronide, accounting for 10–20% of the administered dose.
Adverse events are those common to fluoroquinolones, in particular gastrointestinal tract disturbances, CNS effects (mainly headache and insomnia) and rashes. Photosensitivity reactions have been observed in 2–11% of patients. It can prolong the QTc interval and cases of torsade de pointes have been reported. It does not potentiate the toxicity of theophylline.
It has been used for respiratory and other infections caused by susceptible bacteria, but use has been restricted in the USA and Europe because of phototoxicity and cardiotoxicity.

Clinical Use

Sparfloxacin, (cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl)-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylicacid, is a newer fluoroquinolone.
This compound exhibits higher potency against Grampositivebacteria, especially staphylococci and streptococci,than the fluoroquinolones currently marketed. It is also moreactive against chlamydia and the anaerobe Bacteroides fragilis.The activity of sparfloxacin against Gram-negative bacteriais also very impressive, and it compares favorably withciprofloxacin and ofloxacin in potency against Mycoplasmaspp., Legionella spp., Mycobacteria spp., and Listeria monocytogenes.Sparfloxacin has a long elimination half-life of18 hours, which permits once-a-day dosing for most indications.The drug is widely distributed into most fluidsand tissues. Effective concentrations of sparfloxacin areachieved for the treatment of skin and soft tissue infections,lower respiratory infections (including bronchitis and bacterialpneumonias), and pelvic inflammatory disease causedby gonorrhea and chlamydia. Sparfloxacin has also beenrecommended for the treatment of bacterial gastroenteritisand cholecystitis. The oral bioavailability of sparfloxacinis claimed to be good, and sufficient unchanged drug isexcreted to be effective for the treatment of urinary tract infections.Nearly 20% of an orally administered dose is excretedas an inactive glucuronide.

Sparfloxacin Preparation Products And Raw materials

Raw materials

Preparation Products


Sparfloxacin Suppliers

Global( 248)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Hangzhou FandaChem Co.,Ltd.
008615858145714
+86-571-56059825 fandachem@gmail.com CHINA 8909 55
Guangzhou PI PI Biotech Inc
+8618371201331
020-81716319 sales@pipitech.com;87478684@qq.com China 3245 55
Hubei Jusheng Technology Co.,Ltd.
86-18871470254
027-59599243 linda@hubeijusheng.com CHINA 28229 58
Henan Xiangtong Chemical Co., Ltd.
86-371-61312303
86-371-86017988 cathy@hnxtchem.com CHINA 293 58
Hubei xin bonus chemical co. LTD
86-13657291602
027-59338440 linda@hubeijusheng.com CHINA 23035 58
CONIER CHEM AND PHARMA LIMITED
86-18523575427
sales@conier.com CHINA 47498 58
career henan chemical co
13203830695 0086-371-86658258
0086-371-86658258 factory@coreychem.com CHINA 29864 58
Shaanxi Dideu Medichem Co. Ltd
18192627656
+86-29-88380327 1012@dideu.com CHINA 3949 58
Target Molecule Corp
18019718960 781-999-5354
marketing@targetmol.com United States 19232 58
Hefei TNJ Chemical Industry Co.,Ltd.
0551-65418671
0551-65418697 sales@tnjchem.com CHINA 37441 58

View Lastest Price from Sparfloxacin manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2021-08-25 Sparfloxacin
110871-86-8
US $1.00 / KG 1KG 99% 10T Henan Xiangtong Chemical Co., Ltd.
2021-07-20 Sparfloxacin USP/EP/BP
110871-86-8
US $1.10 / g 1g 99.9% 100 Tons min Dideu Industries Group Limited
2020-05-13 Sparfloxacin
110871-86-8
US $0.01-1.00 / KG 1KG 99% 50 tons Shaanxi Dideu Medichem Co. Ltd

110871-86-8(Sparfloxacin)Related Search:


Copyright 2017 © ChemicalBook. All rights reserved